Treatment of cancer with a RAF inhibitor
Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.
1 . A method of treating a cancer in a patient in need thereof, comprising administering to the patient (S)—N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, or pharmaceutically acceptable salt or solvate thereof.
2 . The method of claim 1 , wherein the cancer is characterized as having an oncogenic BRAF alteration.
3 . The method of claim 2 , wherein the oncogenic BRAF alteration is a BRAF V600 mutation.
4 . The method of claim 3 , wherein the BRAF V600 mutation is a V600E or V600K mutation.
5 . The method of claim 1 , wherein the cancer is characterized as having a wild type BRAF.
6 . The method of claim 1 , wherein the cancer is a solid tumor.
7 . The method of claim 1 , wherein the cancer is selected from melanoma, pancreatic cancer, pancreatic adenocarcinoma, ovarian cancer, colorectal cancer, glioma, Langerhans cell histiocytosis, leukemia, hairy cell leukemia, thyroid cancer, anaplastic thyroid cancer, papillary thyroid carcinoma, follicular thyroid carcinoma, or medullary thyroid carcinoma.
8 . The method of claim 1 , wherein the cancer is selected from small cell lung cancer, non-small cell lung cancer, prostate cancer, gastric cancer, esophageal cancer, NRAS mutant melanoma, or colorectal cancer.
9 . The method of claim 1 , wherein the cancer is metastatic.
10 . The method of claim 1 , wherein the method is adjuvant therapy following surgical resection.
11 . The method of claim 1 , wherein the patient has relapsed after prior therapy, has acquired resistance to prior therapy, or is refractory to therapy.
12 . The method of claim 1 , wherein the (S)—N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, or pharmaceutically acceptable salt or solvate thereof, is administered orally.
13 . A method of treating a cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising (S)—N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, or pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.
14 . A method of treating a cancer in a patient in need thereof, comprising administering to the patient:
(a) a composition comprising (S)—N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, or pharmaceutically acceptable salt or solvate thereof; and
(b) at least one oncology therapeutic selected from a MEK inhibitor, an immune checkpoint inhibitor, a CDK inhibitor, an EGFR kinase inhibitor, an EGFR antibody, an EGFR PROTAC therapeutic, a FGFR inhibitor, a SOS1 inhibitor, a SHP2 inhibitor, a KRAS inhibitor, a taxane, a topoisomerase inhibitor, an ERK inhibitor, a platinum-based chemotherapy, folinic acid, 5-fluorouracil, or an anti-VEGF therapeutic.
15 . The method of claim 14 , wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor, a PD-1 inhibitor, or a PD-L1 inhibitor, and the CDK inhibitor is a CDK4/6 inhibitor.
16 . The method of claim 14 , wherein the MEK inhibitor is selected from binimetinib, trametinib, cobimetinib, selumetinib, pimasertib, or mirdametinib; the CTLA-4 inhibitor is ipilimumab; the PD-1 inhibitor is spartalizumab, nivolumab, pembrolizumab, or cemiplimab; the PD-L1 inhibitor is atezolizumab, avelumab, or durvalumab; the CDK4/6 inhibitor is palbociclib, abemaciclib, or ribociclib; the EGFR kinase inhibitor is nazartinib, gefitinib, erlotinib, afatinib, brigatinib, icotinib, neratinib, osimertinib, dacomitinib, or lapatinib; the EGFR antibody is cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab; the KRAS inhibitor is sotorasib, adagrasib, or BI-1701963; the topoisomerase inhibitor is irinotecan, topotecan, or belotecan; the platinum-based chemotherapy is oxaliplatin, cisplatin, or carboplatin; and the anti-VEGF therapeutic is bevacizumab or aflibercept.
17 . The method of claim 14 , wherein the at least one oncology therapeutic is a MEK inhibitor.
18 . The method of claim 17 , wherein the MEK inhibitor is selected from binimetinib, trametinib, cobimetinib, selumetinib, pimasertib, or mirdametinib.
19 . The method of claim 18 , wherein the MEK inhibitor is binimetinib.
20 . The method of claim 14 , wherein the at least one oncology therapeutic is an EGFR antibody.
21 . The method of claim 20 , wherein the EGFR antibody is cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab.
22 . The method of claim 21 , wherein the EGFR antibody is cetuximab.
23 . The method of claim 14 , wherein the cancer is characterized as having an oncogenic BRAF alteration.
24 . The method of claim 23 , wherein the oncogenic BRAF alteration is a BRAF V600 mutation.
25 . The method of claim 24 , wherein the BRAF V600 mutation is a V600E or V600K mutation.
26 . The method of claim 14 , wherein the cancer is characterized as having a wild type BRAF.
27 . The method of claim 14 , wherein the cancer is a solid tumor.
28 . The method of claim 14 , wherein the cancer is selected from melanoma, pancreatic cancer, pancreatic adenocarcinoma, ovarian cancer, colorectal cancer, glioma, Langerhans cell histiocytosis, leukemia, hairy cell leukemia, thyroid cancer, anaplastic thyroid cancer, papillary thyroid carcinoma, follicular thyroid carcinoma, or medullary thyroid carcinoma.
29 . The method of claim 14 , wherein the cancer is selected from small cell lung cancer, non-small cell lung cancer, prostate cancer, gastric cancer, esophageal cancer, NRAS mutant melanoma or colorectal cancer.
30 . The method of claim 14 , wherein the cancer is metastatic.
31 . The method of claim 14 , wherein the method is adjuvant therapy following surgical resection.